Evaluation of Minimal Optimal Dose of Intravenous Ferric Carboxymaltose for Treatment of Iron Deficiency Anemia and Risk of Transient Hyperferritinemia

BACKGROUND: Iron supplementation is administered orally or intravenously to treat iron-deficiency anemia (IDA). Ferric Carboxymaltose (FCM) “Ferinject(®)” is an intravenous (IV) iron preparation that has emerged as a safe therapeutic option for treating IDA in the past decade. AIM: This study aimed...

Descripción completa

Detalles Bibliográficos
Autores principales: Alharbi, Ahmad A, Alharbi, Abdullah A, Bashen, Dhafer Salem, Owaidah, Tarek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677926/
https://www.ncbi.nlm.nih.gov/pubmed/36419736
http://dx.doi.org/10.2147/JBM.S374780

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677926/
https://www.ncbi.nlm.nih.gov/pubmed/36419736
http://dx.doi.org/10.2147/JBM.S374780

Ejemplares similares